Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $123.22 Average Price Target from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have received a consensus rating of “Hold” from the twenty ratings firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and six have assigned a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $122.83.

ZBH has been the topic of several research analyst reports. TD Cowen lowered their price objective on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a research report on Friday, September 6th. Evercore ISI lowered their price target on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. BTIG Research reduced their price objective on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research note on Thursday, October 3rd. Barclays lowered their target price on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research note on Thursday. Finally, Royal Bank of Canada increased their price target on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, November 4th.

Zimmer Biomet Stock Down 0.1 %

Shares of Zimmer Biomet stock opened at $106.74 on Wednesday. Zimmer Biomet has a 12-month low of $101.47 and a 12-month high of $133.90. The firm has a market capitalization of $21.25 billion, a PE ratio of 20.31, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The stock’s fifty day moving average is $107.65 and its 200-day moving average is $108.82.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.65 EPS. Equities analysts anticipate that Zimmer Biomet will post 7.99 earnings per share for the current year.

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds have recently bought and sold shares of the company. Dunhill Financial LLC increased its stake in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares during the period. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet in the 3rd quarter worth approximately $28,000. Bangor Savings Bank acquired a new position in shares of Zimmer Biomet during the third quarter worth approximately $31,000. Family Firm Inc. acquired a new stake in shares of Zimmer Biomet in the second quarter worth $33,000. Finally, Brooklyn Investment Group bought a new position in Zimmer Biomet during the third quarter worth $35,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.